Top 100 PAA Option Holders as at 29/12/2020 with only one variation.variations., page-5

Yappy new year Bucky!

No, they should stick with the current program. It has been one of the great irritations in the past that they've been trying to do everything.

The whole point of doing the dogs first was to create and fine tune a pill most likely to present the least tolerance issues (a big problem for all mTOR drugs) with the (most likely) greatest effectiveness in humans. The point of the current human MND trial is 1. MND, and 2. optimise the pill for other human treatments like cancer. So far there have been no reports of adverse reactions from the MND trial which is a great step forward for the planned phase 2 human cancer trial. Things need to be done in the right order.

Now, that the new year has sprung, I'd like to put a thought out there for consideration.

Imagine that way, way down the track the company is still struggling for a deal, and money's become an even bigger issue and the top investors are finally thinking something must be changed. What to do? Should we consider as a plan B to sell some of the huge amount of IP this company has in the pet department to finance the human trials? Say, as a hypothetical example, put up the dog cancer patents for sale to the highest bidder? btw, I'm only suggesting this as a distant possibility; for now I'm very committed to the current program that began last year (and is running half a year late due the the MND trial enrolment difficulties). What do other investors think?